Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillintazobactam in the treatment of diabetic foot infections in the UK

PharmacoEconomics

Volumn 27, Issue 12, 2009, Pages 1045-1056

  Jansen, Jeroen P ^a   Kumar, Ritesh ^b   Carmeli, Yehuda ^c  

^a MAPI VALUES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLEARANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETIC FOOT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENTEROBACTERIACEAE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; COST-BENEFIT ANALYSIS; DECISION TREES; DIABETIC FOOT; DIRECT SERVICE COSTS; DRUG COSTS; DRUG RESISTANCE, BACTERIAL; GREAT BRITAIN; HUMANS; MODELS, BIOLOGICAL; MODELS, ECONOMETRIC; PENICILLANIC ACID; PIPERACILLIN; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 73549104292     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11310080-000000000-00000     Document Type: Article

References (24)

1. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004; 20 Suppl. 1: S68-77
2. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361: 1545-1551
3. Tennvall GR, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics 2000; 18 (3): 225-238
4. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22: 382-387
5. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910
6. Reiber GE. The epidemiology of diabetic foot problems. Diabet Med 1996; 13 Suppl. 1: S6-11
7. Armstrong DG, Liswood PJ, Todd WF. Prevalence of mixed infections in the diabetic pedal wound: a retrospective review of 112 infections. J Am Podiatr Med Assoc 1995; 85: 533-537
8. Calhoun JH, Cantrell J, Cobos J, et al. Treatment of diabetic foot infections: Wagner classification, therapy, and outcome. Foot Ankle 1988; 9: 101-106
9. Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, doubleblinded, multicentre trial. Lancet 2005; 366: 1695-1703
10. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Infect Dis 1983; 5:1033-1048
11. Cohen FL, Tartasky D. Microbial resistance to drug therapy: a review. Amer J Infection Control 1997; 25: 51-64
12. Hanberger H, Hoffmann M, Lindgren S, et al. High incidence of antibiotic resistance among bacteria in four intensive care units at a university hospital in Sweden. Scand J Infect Dis 1997; 29: 607-614
13. Muder RR, Brennen C,Drenning SD, et al.Multiply antibioticresistant gram-negative bacilli in a long-term-care facility: a case control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997; 18 (12): 809-813
14. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183-189
15. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212
16. DiNubile MJ, Friedland I, Chan CY, et al. Bowel colonization with resistant Gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 443-449
17. Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Management 2001; 42: 183-206
18. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683-693
19. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2006
20. UK Department of Health. NHS reference cost, 2003 and national tariff 2004 (payment by results core tools 2004) [online]. Available from URL: http://www.dh.gov.uk/en/ publicationsandstatistics/publications/ publicationspolicy andguidance/dh-4070195 [Accessed 2006 Oct 5]
21. NHS Trust and PCT combined reference cost, 2005 [online]. Available fromURL: http://www.dh.gov.uk/en/publications andstatistics/publications/ publicationspolicyandguidance/ dh-4133221 [Accessed 2006 Oct 5]
22. UK Government Actuary Department 2002-2004. Available from URL: http://www.gad.gov.uk/Life-Tables/docs/ [Accessed 2006 Oct 1]
23. Sullivan S, Lew D, Devine E, et al. Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics 2002; 20 (15): 1079-1089
24. Nelson EA, O'Meara S, Craig D, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess 2006; 10: iii-iv, ix-x, 1-221